Evidence map›Paper›PMID 32512805›Full record

ReviewAntibiotics (Basel, Switzerland)2020

Growing Trend of Fighting Infections in Aquaculture Environment-Opportunities and Challenges of Phage Therapy.

Justyna D Kowalska, Joanna Kazimierczak, Patrycja M Sowińska, Ewelina A Wójcik, Andrzej K Siwicki, Jarosław Dastych

Abstract readReview
In one paragraph

Review in Antibiotics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed.

  1. Bacteriophages AgainstViruses · 2026
    Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Bacteriophage PCSE1 as a Potential Strategy AgainstAntibiotics (Basel, Switzerland) · 2025
    Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Current status of clinical trials for phage therapy.Journal of medical microbiology · 2024
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Justyna D KowalskaProteon Pharmaceuticals, 90-364 Lodz, Poland.
Joanna KazimierczakProteon Pharmaceuticals, 90-364 Lodz, Poland.
Patrycja M SowińskaProteon Pharmaceuticals, 90-364 Lodz, Poland.
Ewelina A WójcikProteon Pharmaceuticals, 90-364 Lodz, Poland.
Andrzej K SiwickiDepartment of Microbiology and Clinical Immunology, Faculty of Veterinary Medicine, University of Warmia and Mazury, 10-719 Olsztyn, Poland.
Jarosław DastychProteon Pharmaceuticals, 90-364 Lodz, Poland.

Funding

European Regional Development Fund POIG.01.04.00-10-098 / 12-00
6 · The paper itself

Abstract

Phage therapy, a promising alternative to antimicrobial treatment of bacterial diseases, is getting more and more popular, especially due to the rising awareness of antibiotic resistance and restrictions in antibiotics' use. During recent years, we observed a growing trend of bacteriophages' application in aquaculture, which in each year reports high losses due to bacterial diseases. This review provides an update of the status of bacteriophage therapy for the treatment and prevention of infections in the aquatic environment. As it is still mostly in the scientific stage, there are a few constraints that may prevent effective therapy. Therefore, specific characteristics of bacteriophages, that can act in favor or against their successful use in treatment, were described. We underlined aspects that need to be considered: specificity of phages, bacterial resistance, safety, immune response of the host organism, formulation, administration and stability of phage preparations as well as bacteriophages' influence on the environment. The biggest challenge to overcome is finding the right balance between the desired and problematic characteristics of bacteriophages. Finally, regulatory approval challenges may be encountered by bacteriophage manufacturers. Even though there are still some technical constraints connected with the global use of bacteriophage therapy, it was concluded that it can be successfully applied in aquaculture.

Indexed as

antibiotic resistanceaquaculturepathogenic bacteriaphagephage therapy

Identifiers

PMID32512805
PMCPMC7345527

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.